NEW YORK, April 30, 2024 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, today announced that its board of directors has authorized the repurchase of up to 1,000,000 shares of the Company's outstanding common stock.
Purchases may be made, from time to time, in the open market and will be funded from available cash. The number of shares to be purchased and the timing of purchases will be based on the level of Travelzoo's cash balances, general business and market conditions, and other factors, including alternative investment opportunities.
About Travelzoo We, Travelzoo®, are the club for travel enthusiasts. Our 30 million members receive exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers?our long-standing relationships give Travelzoo members access to irresistible deals.
Day 1 of the London Blockchain Conference kicks off today with world-renowned marketing and business entrepreneur and professor Scott Galloway taking the stage.
Tech influencer Lilly Douse will also host this year's conference. She will bring her...
Sungrow, the global leading PV inverter and energy storage system provider, has forged a strategic partnership with Larsen & Toubro to supply 165MW PV inverters and 160MW/760MWh energy storage systems for AMAALA, a prestigious destination in Saudi...
Allied Market Research published a report, titled, "Managed Learning Service Market by Type (Sourcing External Training, L&D Administration, Supplier Management, and Others), Enterprise Size (Small & Medium Enterprises and Large Enterprises),...
Configit, a global leader in Configuration Lifecycle Management (CLM), today announced that Knauf Digital GmbH, a subsidiary of the Knauf Group, has implemented Configit Ace® SaaS to accelerate its Configure, Price, Quote (CPQ) process. Configit's...
Today sees the launch of the Leandro Herrero Institute; a membership community for leaders and professionals who want to directly benefit from Leandro's unique experience, expertise and insights. This was gained from his 25+ years pioneering a better...
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...
